...
机译:JAK2(EX13INDEL)驱动致癌转化,与慢性嗜酸性白血病和多胆症VERA相关
Univ Utah Div Hematol &
Hematol Malignancies Salt Lake City UT USA;
Univ Utah Huntsman Canc Inst Salt Lake City UT USA;
Catholic Univ Louvain Ludwig Canc Res Brussels Brussels Belgium;
Univ Utah Huntsman Canc Inst Salt Lake City UT USA;
Univ Utah Huntsman Canc Inst Salt Lake City UT USA;
Catholic Univ Louvain Ludwig Canc Res Brussels Brussels Belgium;
Univ Utah Sch Med Dept Biochem Salt Lake City UT USA;
Univ Utah Huntsman Canc Inst Salt Lake City UT USA;
Univ Utah Huntsman Canc Inst Salt Lake City UT USA;
Univ Utah Sch Med Dept Pathol Div Clin Pathol Salt Lake City UT USA;
Univ Utah Div Hematol &
Hematol Malignancies Salt Lake City UT USA;
Royal Derby Hosp Dept Haematol Derby England;
Univ Coll London Hosp Dept Clin Haematol London England;
Salisbury NHS Fdn Trust Wessex Reg Genet Lab Salisbury Wilts England;
Univ Utah Dept Dermatol Salt Lake City UT USA;
Salisbury NHS Fdn Trust Wessex Reg Genet Lab Salisbury Wilts England;
Catholic Univ Louvain Ludwig Canc Res Brussels Brussels Belgium;
Univ Utah Div Hematol &
Hematol Malignancies Salt Lake City UT USA;
Univ Utah Div Hematol &
Hematol Malignancies Salt Lake City UT USA;
Univ Utah Div Hematol &
Hematol Malignancies Salt Lake City UT USA;
机译:JAK2(EX13INDEL)驱动致癌转化,与慢性嗜酸性白血病和多胆症VERA相关
机译:鲁索替尼和达沙替尼治疗的 JAK2 i> V617F阳性红细胞增多症和 BCR-ABL i>阳性慢性粒细胞性白血病
机译:3例来自两个独立造血干细胞的患者同时发生JAK2 V617F阳性真性红细胞增多症和B细胞慢性淋巴细胞性白血病
机译:TEL / JAK2融合蛋白与人类白血病相关的转化和信号转导特性的表征。
机译:鲁索替尼和达沙替尼治疗JAK2 V617F阳性真性红细胞增多症和BCR-ABL阳性慢性粒细胞性白血病
机译:JAK2 EX13INDEL驱动致癌转化,与慢性嗜酸性白血病和多胆症VERA相关
机译:恶性淋巴瘤,慢性淋巴细胞白血病和颗粒细胞白血病和多发性白血病患者全身照射(50 R至100 R)的血液学和治疗效果